These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19583834)

  • 1. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.
    Li CY; Li BX; Liang Y; Peng RQ; Ding Y; Xu DZ; Zhang X; Pan ZZ; Wan DS; Zeng YX; Zhu XF; Zhang XS
    J Transl Med; 2009 Jul; 7():56. PubMed ID: 19583834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
    Li XF; Guo XG; Yang YY; Liu AY
    Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients.
    Coco C; Zannoni GF; Caredda E; Sioletic S; Boninsegna A; Migaldi M; Rizzo G; Bonetti LR; Genovese G; Stigliano E; Cittadini A; Sgambato A
    J Exp Clin Cancer Res; 2012 Sep; 31(1):71. PubMed ID: 22964035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
    Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
    Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD133 expression is correlated with poor prognosis in colorectal cancer.
    Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
    Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
    Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
    JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
    Xi HQ; Zhao P
    J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
    Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
    J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker.
    Schneider M; Huber J; Hadaschik B; Siegers GM; Fiebig HH; Schüler J
    BMC Cancer; 2012 Mar; 12():96. PubMed ID: 22433494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
    Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
    Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
    Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AC133 expression associated with poor prognosis in stage II colorectal cancer.
    Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
    Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
    J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
    Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.
    Alamgeer M; Ganju V; Szczepny A; Russell PA; Prodanovic Z; Kumar B; Wainer Z; Brown T; Schneider-Kolsky M; Conron M; Wright G; Watkins DN
    Thorax; 2013 Dec; 68(12):1095-104. PubMed ID: 23878161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.
    Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D
    World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma.
    Mărgaritescu C; Pirici D; Cherciu I; Bărbălan A; Cârtână T; Săftoiu A
    J Gastrointestin Liver Dis; 2014 Jun; 23(2):161-70. PubMed ID: 24949608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.